1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6211)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13088)
  2. Department of Medicine (13004)
  3. Center for Hematologic Malignancies (10395)
  4. GSK Faculty (4422)
  5. Adult Leukemia (3583)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (775)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (204)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (431)

More Publishers

Results (13088)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Subcutaneous epcoritamab + R-DHAX/C in patients with relapsed or refractory diffuse large B-cell lymphoma eligible for autologous stem cell transplant: Updated phase 1/2 results
    Meeting Abstract

    Abrisqueta, P.; Cordoba, R.; Falchi, L.; de Vos, S.; Nijland, M.; Offner, F.; Wu, J.; Bykhovski, I.; Wang, L.; Rana, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A simplified patient care strategy to decrease early deaths in acute promyelocytic leukemia (APL): Results of the ECOG-ACRIN EA9131 trial
    Meeting Abstract

    Jillella, A. P.; Lee, S. J.; Altman, J. K.; Luger, S. M.; Tallman, M. S.; Foran, J. M.; Law, L. Y.; Bryan, L. J.; Abou Zahr, A.; Begna, K.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin combined with R-ICE (PolaR-ICE) as second-line therapy in relapsed/refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Herrera, A. F.; Chen, L.; Crombie, J. L.; Cohen, J. B.; Advani, R. H.; LaCasce, A. S.; Popplewell, L. L.; Puverel, S.; Peters, L.; Daniels, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Relapse is uncommon in patients with large B-cell lymphoma who are in complete remission at the end of fixed-course glofitamab treatment
    Meeting Abstract

    Hutchings, M.; Carlo-Stella, C.; Morschhauser, F.; Bachy, E.; Corradini, P.; Iacoboni, G.; Khan, C.; Patel, K.; Hertzberg, M.; Falchi, L.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed / refractory Waldenström macroglobulinemia: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Palomba, M. L.; Patel, M. R.; Eyre, T. A.; Jurczak, W.; Lewis, D. J.; Gastinne, T.; Ma, S.; Cohen, J. B.; Patel, K.; Brown, J. R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Allogeneic but not autologous stem cell transplantation improves outcome in HTLV-1-associated North American adult T-cell leukemia/lymphoma
    Meeting Abstract

    Bazarbachi, A. H.; Reef, D. K.; Narvel, H.; Patel, R.; Al Hamed, R.; Thakkar, A.; Rahman, S.; Shah, U. A.; Herrera, D. A.; Quinn, R.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma naïve to B-cell maturation antigen (BCMA)-directed therapies: Results from Cohort A of the MagnetisMM-3 study
    Meeting Abstract

    Bahlis, N. J.; Tomasson, M. H.; Mohty, M.; Niesvizky, R.; Nooka, A. K.; Manier, S.; Maisel, C.; Jethava, Y.; Martinez-Lopez, J.; Prince, H. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: Results from the phase 1/2 BRUIN study
    Meeting Abstract

    Wierda, W. G.; Lewis, D. J.; Ghia, P.; Shah, N. N.; Coombs, C. C.; Cheah, C. Y.; Lamanna, N.; Rhodes, J. M.; Hoffmann, M.; Ma, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of vodobatinib in patients (pts) with chronic phase Philadelphia positive chronic myeloid leukemia (Ph + CML): A sub group analysis by lines of tyrosine kinase inhibitor (TKI) therapy
    Meeting Abstract

    Cortes, J. E.; Saikia, T.; Kim, D. W.; Alvarado, Y.; Nicolini, F. E.; Rathnam, K.; Khattry, N.; Punatar, S.; Apperley, J. F.; Charbonnier, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Pelabresib (CPI-0610) combined with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis: Durability of response and safety beyond week 24
    Meeting Abstract

    Mascarenhas, J.; Kremyanskaya, M.; Patriarca, A.; Gupta, V.; Palandri, F.; Devos, T.; Rampal, R. K.; Talpaz, M.; Vannucchi, A.; Kuykendall, A.; more...
    Blood (2022)

    Fulltext@MSK | Save